NetMHCstab - Predicting stability of peptide-MHC-I complexes; impacts for cytotoxic T lymphocyte epitope discovery

Immunology

Volumn 141, Issue 1, 2014, Pages 18-26

  Jørgensen, Kasper W ^a   Rasmussen, Michael ^b   Buus, Søren ^b   Nielsen, Morten ^a,c  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

Author keywords

Cytotoxic T lymphocyte epitopes; Immunoinformatics; MHC peptide stability; Peptide immunogenicity

Indexed keywords

EPITOPE; HLA A ANTIGEN; HLA B ANTIGEN; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ARTICLE; ARTIFICIAL NEURAL NETWORK; BINDING AFFINITY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STABILITY;

CYTOTOXIC T LYMPHOCYTE EPITOPES; IMMUNOINFORMATICS; MHC-PEPTIDE STABILITY; PEPTIDE IMMUNOGENICITY;

CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERNET; MODELS, IMMUNOLOGICAL; NEURAL NETWORKS (COMPUTER); PEPTIDES;

EID: 84889637320     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12160     Document Type: Article

References (27)

1. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51-88.
2. Lundegaard C, Lund O, Nielsen M. Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy? Expert Rev Vaccines 2012; 11:43-54.
3. Lundegaard C, Lund O, Buus S, Nielsen M. Major histocompatibility complex class I binding predictions as a tool in epitope discovery. Immunology 2010; 130:309-18.
4. Assarsson E, Sidney J, Oseroff C et al. A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol 2007; 178:7890-901.
5. Busch DH, Pamer EG. MHC class I/peptide stability: implications for immunodominance, in vitro proliferation, and diversity of responding CTL. J Immunol 1998; 160:4441-8.
6. Lazarski CA, Chaves FA, Jenks SA et al. The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity 2005; 23:29-40.
7. van der Burg SH, Visseren MJ, Brandt RM, Kast WM, Melief CJ. Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol 1996; 156:3308-14.
8. Harndahl M, Rasmussen M, Roder G et al. Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol 2012; 42:1405-16.
9. Harndahl M, Rasmussen M, Roder G, Buus S. Real-time, high-throughput measurements of peptide-MHC-I dissociation using a scintillation proximity assay. J Immunol Methods 2011; 374:5-12.
10. Lund O, Nielsen M, Kesmir C et al. Definition of supertypes for HLA molecules using clustering of specificity matrices. Immunogenetics 2004; 55:797-810.
11. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999; 50:201-12.
12. Karosiene E, Lundegaard C, Lund O, Nielsen M. NetMHCcons: a consensus method for the major histocompatibility complex class I predictions. Immunogenetics 2011; 64:177-86.
13. Nielsen M, Lundegaard C, Worning P et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci 2003; 12:1007-17.
14. + T cell responses. J Immunol 2009; 182:1526-32.
15. Stranzl T, Larsen MV, Lundegaard C, Nielsen M. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics 2010; 62:357-68.
16. Hoof I, Peters B, Sidney J et al. NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics 2009; 61:1-13.
17. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999; 50:213-9.
18. Vita R, Zarebski L, Greenbaum JA et al. The immune epitope database 2.0. Nucleic Acids Res 2010; 38:D854-62.
19. Lamberth K, Roder G, Harndahl M et al. The peptide-binding specificity of HLA-A*3001 demonstrates membership of the HLA-A3 supertype. Immunogenetics 2008; 60:633-43.
20. Erup Larsen M, Kloverpris H, Stryhn A et al. HLArestrictor - a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 2011; 63:43-55.
21. Magrane M, Consortium U. UniProt Knowledgebase: a hub of integrated protein data. Database 2011; 2011:bar009.
22. Andreatta M, Lund O, Nielsen M. Simultaneous alignment and clustering of peptide data using a Gibbs sampling approach. Bioinformatics 2013; 29:8-14.
23. Kullback S, Leibler RA. On information and sufficiency. Ann Math Stat 1951; 22:76-86.
24. Parker KC, Bednarek MA, Hull LK et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. J Immunol 1992; 149:3580-7.
25. Buus S, Sette A, Colon SM, Miles C, Grey HM. The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science 1987; 235:1353-8.
26. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994; 152:163-75.
27. Thomsen MC, Nielsen M. Seq2Logo: a method for construction and visualization of amino acid binding motifs and sequence profiles including sequence weighting, pseudo counts and two-sided representation of amino acid enrichment and depletion. Nucleic Acids Res 2012; 40:W281-7.